Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase III Trial of Roflumilast Cream in Atopic Dermatitis
Arcutis Biotherapeutics, Inc. announced the enrollment of the last subject in its INTEGUMENT-1 pivotal Phase III trial of roflumilast cream 0.15% in adults and children with atopic dermatitis.
[Oncogenesis] By using both mouse and human TNBC cell lines, investigators found that diltiazem decreased colony formation and cell migration in breast cancer cells.
[Nature Cell Biology] Researchers discovered that a C2H2 zinc finger protein, ZNF827, is strongly induced during various contexts of epithelial-to-mesenchymal transition (EMT), including in brain development and breast cancer metastasis.
[Molecular Therapy Oncolytics] In an ex vivoassay, the size of freshly isolated human breast cancer tissues, including ER-positive & negative as well as HER2-positive & negative, was reduced by YS49-treated mesenchymal stem cell (MSC) derived conditioned medium.